- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04122742
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. (GENEPI)
Rubinstein-Taybi syndrome (RSTS) is a rare and severe congenital developmental disorder characterized by congenital anomalies and intellectual disability with a long term memory deficit. The main challenge is to improve the intellectual and memory efficiency of these patients. CREBBP and EP300 are the two genes known to cause RSTS. Both paralogs play a major role in chromatin remodeling and encode for transcriptional co-activators interacting with many proteins.
The aim of this pilot study is to characterize the histone acetylation profiles in order to identify specific acetylation markers during normal and pathological neuronal differentiation of cortical and pyramidal neurons in RSTS.
Study Overview
Status
Conditions
Intervention / Treatment
- Procedure: skin biopsy for the primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of 5ml) in each of the 4 SRT patients included.
- Other: Generation of Induced Pluripotent Stem Cells (iPSC) from fibroblasts obtained by skin biopsy
- Other: Histone acetylation profiles of cells of SRT patients with CREBBP mutations
- Other: Functional involvement of identified epigenetic alterations
- Biological: Culture of lymphoblastoid line from blood sample
Detailed Description
CREBBP and EP300 are the two paralog genes associated with RSTS determinism and code for CBP and p300, respectively. These proteins are transcriptional coactivators that possess a catalytic lysine acetyl transferase (KAT) domain involved in the acetylation of lysine residues of histones but also other proteins. CBP and p300 promote transcription by creating a chromatin environment that is favorable for gene expression and by linking different transcription factors to each other. They thus orchestrate the regulation of the transcription machinery, from the basal promoter to the enhancers of the target genes.
RSTS is considered a genetic model of neurodevelopmental anomaly with an epigenetic component.
Histone acetylation is one of the major post-translational modifications (PTMs) of these proteins that provide for the formation and control of chromatin structure. When differentiating embryonic cells, this modification plays a key role in transcriptional activation.
The mouse models of RSTS have made the link between the modulation of histone acetylation and the formation of memory by showing their key role in neuronal plasticity. However no data exists on the acetylation of histones in the neurons of RSTS patients. Furthermore, in humans, the molecular pathways impacted by these alterations during neurodevelopment are not specified, especially in the pyramidal neurons which are the precursors of hippocampal neurons involved in the encoding and storage of memory.
In RSTS a loss of CBP function results in a deficit in KAT activity, which is responsible for altering histone acetylation, leading to inappropriate changes in chromatin structure. The consequence of a mutation is a result of a deregulation of the activity of genes involved in development. No neuronal level studies are currently available on the functional link between histone acetylation and deregulated genes in the RSTS.
In this project, investigators will identify target genes whose epigenetic regulation is mediated by histone acetylation. More specifically, the study will focus on chromatin dynamics during normal and pathological neuronal differentiation of cortical and pyramidal neurons. Investigators will determine among the CBP-dependent histone markers, those that are modified in RSTS patients cells and the loci they control. In parallel, investigators will define genes whose neuronal expression is altered in RSTS patients.
The integration of all these data will allow us to specify which genes are deregulated during neuronal differentiation as a consequence of CBP lysine acetyltransferase function loss.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Julien VAN-GILS
- Phone Number: +33 5 57 82 03 53
- Email: julien.van-gils@chu-bordeaux.fr
Study Locations
-
-
-
Talence, France, 33400
- Recruiting
- Centre Hospitalier Universitaire de Bordeaux
-
Contact:
- Julien VAN-GILS
- Phone Number: +33 5 57 82 03 53
- Email: julien.van-gils@chu-bordeaux.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient with a clinical and molecular diagnosis of RSTS
- Patients carrying the CREBBP or EP300 variants
- Patients older than 2 years
- Affiliated patients or beneficiaries of a social security scheme.
- Free, informed and signed consent by the parents or holder of parental authority for minor patients
- Free, informed and signed consent by the patient representative for the major patients under guardianship
- Free, informed and signed consent by the patient for major patients
Exclusion Criteria:
Patients having:
- a history of allergy to any product or device that may be used before, during, and after the biopsy;
- cutaneous disease of the areas where the biopsy is to be performed
- underwent physical treatment (radiotherapy, ...) on the area to be biopsied, during the last 6 months
- hereditary or acquired disorders of hemostasis
Patients under treatment:
- likely to act on the haemostasis (anticoagulants, platelet antiaggregants, ...) in the month preceding the inclusion and during the study
- by histone deacetylase inhibitor (sodium valproate) likely to interfere with the interpretation of the results.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with RSTS
|
Performed with a 3 mm diameter punch under local anesthesia.
The procedure can be done in a consultation office respecting a strict asepsis.
induced Pluripotent Stem Cells (iPSC) production of patients with CREBBP mutation and differentiation into cortical neurons and pyramidal neurons
Study of acetylome by liquid chromatography coupled with tandem mass spectrometry (LC-MS / MS) Validation of specific acetylation targets by ChIP-Sequencing
Transcriptome analysis with RNA-Seq Generation of isogenic iPSC clones by correction of CREBBP mutations in SRT patients by CrispR-Cas9.
Achievement of a ficoll Culture of lymphoblasts and conservation Establishment of lymphoblastoid line and conservation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of a specific acetylation profile of RSTS
Time Frame: Inclusion visit
|
From skin biopsy sample collected at inclusion visit :
|
Inclusion visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of different target genes between SRT patients and controls
Time Frame: Inclusion visit
|
SRT patients will be compared to 4 control cell cultures from healthy volunteers matched for age and sex already available
|
Inclusion visit
|
Evidence of a significantly different level of expression for common target genes for RSTS patients and controls
Time Frame: Inclusion visit
|
Inclusion visit
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Musculoskeletal Diseases
- Bone Diseases
- Intellectual Disability
- Craniofacial Abnormalities
- Musculoskeletal Abnormalities
- Abnormalities, Multiple
- Chromosome Disorders
- Bone Diseases, Developmental
- Dysostoses
- Rubinstein-Taybi Syndrome
Other Study ID Numbers
- CHUBX 2019/19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rubinstein-Taybi Syndrome
-
University Hospital, BordeauxFondation Syndrome de Rubinstein-TaybiCompletedRubinstein-Taybi SyndromeFrance
-
Hospices Civils de LyonUnknownGenetic Syndrome | Taybi Linder SyndromeFrance
-
Hospices Civils de LyonNot yet recruitingLowry Wood Syndrome | Roifman Syndrome | Taybi Linder Syndrome | Microcephalic Osteodysplastic Primordial Dwarfism Types I and IIIFrance
-
University Hospital, BordeauxRecruitingIntellectual Disability | Cystic Fibrosis | Neurodegeneration With Brain Iron Accumulation (NBIA) | Congenital Heart Defect | Albinism | Rubinstein-Taybi Syndrome | Periventricular Nodular HeterotopiaFrance
-
Neumedicines Inc.Department of Health and Human ServicesCompletedHematopoietic Syndrome Due to Acute Radiation SyndromeUnited States
-
Ministry of Public Health, Democratic Republic...National Institutes of Health (NIH); Oregon Health and Science University; National... and other collaboratorsCompletedNeurotoxicity Syndrome, Cassava | Neurotoxicity Syndrome, Cyanate | Neurotoxicity Syndrome, Cyanide | Neurotoxicity Syndrome, ThiocyanateCongo, The Democratic Republic of the
-
Mahidol UniversityCompletedSubacromial Impingement Syndrome | Shoulder Impingement Syndrome | Subacromial Pain Syndrome | Subacromial Impingement | Impingement Syndrome, ShoulderIndonesia
-
Cliniques universitaires Saint-Luc- Université...TerminatedMultiple Organ Dysfunction Syndrome | SEPTIC SHOCK | SEPSIS SYNDROMEBelgium
-
University of PennsylvaniaRecruitingCRS - Cytokine Release Syndrome | HLHUnited States
-
University of ManitobaTerminatedPatellofemoral Pain Syndrome | Anterior Knee Pain Syndrome | Patellofemoral SyndromeCanada
Clinical Trials on skin biopsy for the primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of 5ml) in each of the 4 SRT patients included.
-
Centre Hospitalier de CayenneEuropean Regional Development FundRecruitingChildren | Dengue Fever | AdultsFrance
-
Memorial Sloan Kettering Cancer CenterTufts Medical Center; Lahey ClinicCompleted